Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GeneLink distribution deal

This article was originally published in The Tan Sheet

Executive Summary

Start-up direct marketer NuGenix expects to begin selling customized nutritional products developed using GeneLink technology in Q3. Under distribution agreement announced May 8, NuGenix will use GeneLink's patented DNA Collection Kit and nutragenetic assessment system to provide its network of distributors with a customized nutritional regimen consisting initially of approximately six formulas; supplements will be developed and manufactured by Vitaquest division Garden State Nutritionals (1"The Tan Sheet" Oct. 8, 2001, p. 14). Philadelphia-based NuGenix is hoping to attract distributors from other direct marketers both inside and outside the supplement industry...

You may also be interested in...

Genetic Technology Enters Supplement Industry With GSN, GeneLink Deal

Garden State Nutritionals will offer five dietary supplements tailored for consumers' varying genetic capacities to combat certain types and degrees of oxidative stress, according to the firm.

Roche Continues To Make The Case For Gantenerumab In Alzheimer’s Disease

The amyloid-targeting drug is years behind Biogen/Eisai’s aducanumab, but its subcutaneous administration and the GRADUATE studies’ design could give Roche’s gantenerumab an advantage.

Brinavess' US Review: EU Postmarket Data Unlikely To Save Troubled AFib Drug

Correvio's atrial fibrillation drug Brinavess will return to a US FDA advisory committee more than a decade after the agency first declined to approve the drug;  FDA still has a series of cardiovascular safety concerns related to the drug and is not convinced by data from the European experience.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts